

European Directorate for the Quality of Medicines & HealthCare

Council of Europe







* * * * ne 4

CombiStats online Training module 4

Part 1: single-dose assays

Part 2: combination of assay results





Content

- ★ Data entry
- ★ Statistical analysis
- ★ Examples
- ★ Dose selection



Data entry – quantitative data

E.g. immunogenicity test in mice

Preparations

| | | Information | Potency | | Pre-dilution | |
|----------|-------------|-------------|------------------|-------------|--------------|--------------|
| Table | Preparation | ID | Potency | Value | Diluted | Injected |
| 1 | Standard 🕶 | Reference | Assigned | 1 unit/dose | 1 dose/2 ml | 0.5 ml/mouse |
| 2 | Sample 1 ▼ | Batch | Assumed ▼ | 1 unit/dose | 1 dose/ml | 0.5 ml/mouse |

| Table 1 | | | |
|-------------------------|-------------------------|--|--|
| Preparation | Standard | | |
| ID | Reference | | |
| Potency | Assigned | | |
| Potency value | 1 unit/dose | | |
| Diluted | 1 dose/2 ml | | |
| Injected | 0.5 ml/mouse | | |
| | | | |
| Dose | 1/1 | | |
| Dose Rep.1 | 1/1 0.867 | | |
| | | | |
| Rep.1 | 0.867 | | |
| Rep.1 Rep.2 | 0.867 0.568 | | |
| Rep.1 Rep.2 Rep.3 | 0.867 0.568 0.674 | | |

| Table 2 | | |
|-----------------|----------------|--|
| Preparation | Sample 1 | |
| ID Batch | | |
| Potency | Assumed | |
| Potency value | 1 unit/dose | |
| Diluted | 1 dose/ml | |
| Injected | 0.5 ml/mouse | |
| Dose | 1/1 | |
| | | |
| Rep.1 | 1.068 | |
| Rep.1 Rep.2 | 1.068 0.845 | |
| | | |
| Rep.2 | 0.845 | |
| Rep.2 Rep.3 | 0.845 | |

or

Raw data

| Table 1 | | | |
|---------------|--------------|--|--|
| Preparation | Standard | | |
| ID | Reference | | |
| Potency | Assigned | | |
| Potency value | 1 unit/dose | | |
| Diluted | 1 dose/2 ml | | |
| Injected | 0.5 ml/mouse | | |
| Dose | 1/1 1/1 | | |
| Rep.1 | 0.867 0.550 | | |
| Rep.2 | 0.568 0.598 | | |
| Rep.3 | 0.674 0.732 | | |

| | Table 2 | | | |
|--------------------|---------------|-------|-------|--|
| Preparation | tion Sample 1 | | | |
| ID | Batch | Batch | | |
| Potency | Assum | ed | | |
| Potency value | 1 unit/dose | | | |
| Diluted | 1 dose/ml | | | |
| Injected 0.5 ml/mo | | | | |
| Dose | 1/1 1/1 1/1 | | | |
| Rep.1 | 1.068 | 1.274 | 0.964 | |
| Rep.2 | 0.845 | 0.686 | 1.160 | |

Unique dose repeated in different columns (or rows)



Data entry – quantal data

E.g. in vivo test

Preparations

| | | Information | Potency | |
|----------|-------------|----------------|------------------|-----------|
| Table | Preparation | ID | Potency | Value |
| 1 | Standard 🕶 | Reference | Assigned | 8 IU/ml |
| 2 | Sample 1 ▼ | Potent lot | Assumed ▼ | 2.5 IU/ml |
| 3 | Sample 2 ▼ | Sub-potent lot | Assumed • | 2.5 IU/ml |

Aggregated data (r/n)

Raw data

| Table 1 | | |
|---------------|-----------|--|
| Preparation | Standard | |
| ID | Reference | |
| Potency | Assigned | |
| Potency value | 8 IU/ml | |
| Dose | Rep.1 | |
| 1/300 | 20/28 | |

| Table | 2 | |
|---------------|------------|--|
| Preparation | Sample 1 | |
| ID | Potent lot | |
| Potency | Assumed | |
| Potency value | 2.5 IU/ml | |
| Dose | Rep.1 | |
| 1/30 | 10/28 | |

| Table 3 | | |
|---------------|----------------|--|
| Preparation | Sample 2 | |
| ID | Sub-potent lot | |
| Potency | Assumed | |
| Potency value | 2.5 IU/ml | |
| Dose | Rep.1 | |
| 1/30 | 15/28 | |

Individual data

| Table 1 | | | |
|---------------|-------------|-------|--|
| Preparation | Standard | | |
| ID | Reference | | |
| Potency | Assigned | | |
| Potency value | 8 IU/ml | | |
| Dose | 1/300 1/300 | | |
| Rep.1 | 1 1 | | |
| Rep.2 | 1 | 0 | |
| Rep.3 | 1 | 1 | |
| Rep.4 | 0 | 1 | |
| Rep.5 | 1 | 0 | |
| Rep.6 | 1 | 1 | |
| Rep.7 | 1 | 1 | |
| Rep.8 | 0 | 0 | |
| Rep.9 | 0 | 1 | |
| Rep.10 | 1 | 1 | |
| Rep.11 | 1 | 1 | |
| Rep.12 | 0 | 1 | |
| Rep.13 | 1 | 1 | |
| Rep.14 | 1 | 0 | |
| ×/10 | 10/11 | 10/11 | |

| ■ Tab | Table 2 | | | |
|---------------|---------|------------|--|--|
| Preparation | Sample | Sample 1 | | |
| ID | Potent | Potent lot | | |
| Potency | Assum | ed | | |
| Potency value | 2.5 IU/ | 2.5 IU/ml | | |
| Dose | 1/30 | 1/30 | | |
| Rep.1 | 1 | 0 | | |
| Rep.2 | 0 | 1 | | |
| Rep.3 | 1 | 0 | | |
| Rep.4 | 0 | 0 | | |
| Rep.5 | 0 | 1 | | |
| Rep.6 | 1 | 0 | | |
| Rep.7 | 0 | 0 | | |
| Rep.8 | 0 | 0 | | |
| Rep.9 | 0 | 0 | | |
| Rep.10 | 0 | 1 | | |
| Rep.11 | 1 | 0 | | |
| Rep.12 | 1 | 0 | | |
| Rep.13 | 0 | 1 | | |
| Rep.14 | 1 | 0 | | |
| r/n | 6/14 | 4/14 | | |

| Table 3 | | | |
|---------------|----------------|-----------|--|
| Preparation | Sample 2 | | |
| ID | Sub-potent lot | | |
| Potency | Assumed | | |
| Potency value | 2.5 IU/i | 2.5 IU/ml | |
| Dose | 1/30 | 1/30 | |
| Rep.1 | 0 | 1 | |
| Rep.2 | 1 | 0 | |
| Rep.3 | 1 | 1 | |
| Rep.4 | 0 | 0 | |
| Rep.5 | 1 | 1 | |
| Rep.6 | 0 | 0 | |
| Rep.7 | 1 | 1 | |
| Rep.8 | 1 | 1 | |
| Rep.9 | 1 | 0 | |
| Rep.10 | 0 | 0 | |
| Rep.11 | 0 | 1 | |
| Rep.12 | 1 | 1 | |
| Rep.13 | 1 | 0 | |
| Rep.14 | 0 | 0 | |
| r/n | 8/14 | 7/14 | |





"Show design" option

Quantitative data

Assay layout

| Design | c1 | c2 | с3 |
|--------|-----------|-------|-------|
| r1 | 1 1 1 | 2 1 5 | 1 1 5 |
| r2 | 2 1 3 | 1 1 3 | 1 1 2 |
| r3 | 2 1 6 | 2 1 1 | 2 1 4 |
| r4 | 2 1 2 | 1 1 4 | 1 1 6 |

| Observ. | c1 | c2 | с3 |
|---------|-----------|-------|-------|
| r1 | 0.867 | 0.686 | 0.598 |
| r2 | 0.964 | 0.674 | 0.568 |
| r3 | 1.160 | 1.068 | 1.274 |
| r4 | 0.845 | 0.550 | 0.732 |

Blank results

| 0.002 | 0.007 | 0.005 | 0.004 | 0.007 |
|-------|-------|-------|-------|-------|
| | | | | |

 Mean
 SD
 RSD%

 0.005
 0.002
 42.4

Quantal data (e.g. individual data)

Assay layout

| Design | c1 | c2 | c3 | c4 | c5 | c6 |
|--------|-----------|--------|--------|-----------|-----------|--------|
| r1 | 1 1 1 | 2 1 1 | 3 1 1 | 1 1 15 | 2 1 15 | 3 1 15 |
| r2 | 1 1 2 | 2 1 2 | 3 1 2 | 1 1 16 | 2 1 16 | 3 1 16 |
| r3 | 1 1 3 | 2 1 3 | 3 1 3 | 1 1 17 | 2 1 17 | 3 1 17 |
| r4 | 1 1 4 | 2 1 4 | 3 1 4 | 1 1 18 | 2 1 18 | 3 1 18 |
| r5 | 1 1 5 | 2 1 5 | 3 1 5 | 1 1 19 | 2 1 19 | 3 1 19 |
| r6 | 1 1 6 | 2 1 6 | 3 1 6 | 1 1 20 | 2 1 20 | 3 1 20 |
| r7 | 1 1 7 | 2 1 7 | 3 1 7 | 1 1 21 | 2 1 21 | 3 1 21 |
| r8 | 1 1 8 | 2 1 8 | 3 1 8 | 1 1 22 | 2 1 22 | 3 1 22 |
| r9 | 1 1 9 | 2 1 9 | 3 1 9 | 1 1 23 | 2 1 23 | 3 1 23 |
| r10 | 1 1 10 | 2 1 10 | 3 1 10 | 1 1 24 | 2 1 24 | 3 1 24 |
| r11 | 1 1 11 | 2 1 11 | 3 1 11 | 1 1 25 | 2 1 25 | 3 1 25 |
| r12 | 1 1 12 | 2 1 12 | 3 1 12 | 1 1 26 | 2 1 26 | 3 1 26 |
| r13 | 1 1 13 | 2 1 13 | 3 1 13 | 1 1 27 | 2 1 27 | 3 1 27 |
| r14 | 1 1 14 | 2 1 14 | 3 1 14 | 1 1 28 | 2 1 28 | 3 1 28 |

| Observ. | c1 | c2 | c3 | c4 | с5 | с6 |
|---------|-----------|----|----|----|----|----|
| r1 | 1 | 1 | 0 | 1 | 0 | 1 |
| r2 | 1 | 0 | 1 | 0 | 1 | 0 |
| r3 | 1 | 1 | 1 | 1 | 0 | 1 |
| r4 | 0 | 0 | 0 | 1 | 0 | 0 |
| r5 | 1 | 0 | 1 | 0 | 1 | 1 |
| r6 | 1 | 1 | 0 | 1 | 0 | 0 |
| r7 | 1 | 0 | 1 | 1 | 0 | 1 |
| r8 | 0 | 0 | 1 | 0 | 0 | 1 |
| r9 | 0 | 0 | 1 | 1 | 0 | 0 |
| r10 | 1 | 0 | 0 | 1 | 1 | 0 |
| r11 | 1 | 1 | 0 | 1 | 0 | 1 |
| r12 | 0 | 1 | 1 | 1 | 0 | 1 |
| r13 | 1 | 0 | 1 | 1 | 1 | 0 |
| r14 | 1 | 1 | 0 | 0 | 0 | 0 |






Content

- ★ Data entry
- ★ Statistical analysis
- ★ Examples
- ★ Dose selection




Descriptive plot

Quantitative data




Jittering to prevent overplotting

Quantal data (aggregated)



Quantal data (individual)







Statistical test - quantitative data

A test comparing the location of the data of the preparations

Location = means → t-test (2 preps), multiple comparisons test (> 2 preps)

Assumption: data should be normally distributed (Gauss distributions)

May not be the case for some bioassays...

E.g. immunogenicity test in mice (antibody units) – normal distributions?

CombiStats approach: a test applicable to any distribution (distribution-free statistics); data from a completely randomised design

→ Wilcoxon-Mann-Whitney test

| Table | 1 : |
|---------------|-----------|
| Preparation | Standard |
| ID | S |
| Potency | Assigned |
| Potency value | 1 IU/dose |
| Dose | 1 dose |
| Rep.1 | 4.4 |
| Rep.2 | 12.2 |
| Rep.3 | 8.5 |
| Rep.4 | 8.5 |
| Rep.5 | 1.8 |
| Rep.6 | 7.2 |
| Rep.7 | 7.2 |
| Rep.8 | 8.5 |
| Rep.9 | 3.1 |
| Rep.10 | 10.2 |

| ■ Table | 2 |
|---------------|-----------|
| Preparation | Sample 1 |
| ID | Т |
| Potency | Assumed |
| Potency value | ? IU/dose |
| Dose | 1 dose |
| Rep.1 | 10.2 |
| Rep.2 | 16.9 |
| Rep.3 | 11.7 |
| Rep.4 | 10.2 |
| Rep.5 | 10.2 |
| Rep.6 | 10.2 |
| Rep.7 | 8.5 |
| Rep.8 | 0.1 |
| Rep.9 | 0.1 |
| Rep.10 | 8.5 |





Wilcoxon-Mann-Whitney test

Compares the distributions of results from two preparations

Principle: the values, listed in ascending order, will alternate between the 2 preparations if their underlying distributions are equal

| Tabl | e 1 : |
|---------------|--------------|
| Preparation | Standard |
| ID | Reference |
| Potency | Assigned |
| Potency value | 1 unit/dose |
| Diluted | 1 dose/2 ml |
| Injected | 0.5 ml/mouse |
| Dose | 1/1 |
| Rep.1 | 0.867 |
| Rep.2 | 0.568 |
| Rep.3 | 0.674 |
| Rep.4 | 0.550 |
| Rep.5 | 0.598 |
| Rep.6 | 0.732 |

| Tabl | e 2 |
|---------------|--------------|
| Preparation | Sample 1 |
| ID | Batch |
| Potency | Assumed |
| Potency value | 1 unit/dose |
| Diluted | 1 dose/ml |
| Injected | 0.5 ml/mouse |
| Dose | 1/1 |
| Rep.1 | 1.068 |
| Rep.2 | 0.845 |
| Rep.3 | 0.964 |
| Rep.4 | 1.274 |
| Rep.5 | 0.686 |
| Rep.6 | 1.160 |

Data in ascending order. Do they alternate between the 2 prep? Not really... (have a look at the descriptive plot too)

| Obser | v. c1 | c2 | с3 | c4 | c5 | с6 | c7 | с8 | c9 | c10 | c11 | c12 |
|-------|-------|-------|-------|-------|-----------|-------|-----------|-------|-------|-------|-------|-------|
| r1 | 0.550 | 0.568 | 0.598 | 0.674 | 0.686 | 0.732 | 0.845 | 0.867 | 0.964 | 1.068 | 1.160 | 1.274 |

Rank approach

Std data in position (rank) 1, 2, 3, 4, 6 and 8 Sample data in position (rank) 5, 7, 9, 10, 11 and 12

Limit test

| | | Limit tested | | |
|-----------------|-----------|--------------|-------------|-----------------------|
| Preparation | Units | Value | Probability | Level of significance |
| Sample 1: Batch | unit/dose | 0.5 | 0.007576 | ** |

p-value \leq 0.05 (usual significance threshold) \rightarrow the 2 distributions of results differ significantly





Wilcoxon-Mann-Whitney test

Is useful in a case of skewed data: the **rank approach** relaxes the effects of extreme values

Vero cell assay: values < LOD set to 0

| Table | 1 : |
|---------------|-------------|
| Preparation | Standard |
| ID | S |
| Potency | Assigned |
| Potency value | 160 IU/vial |
| Dose | 1 IU |
| Rep.1 | 0 |
| Rep.2 | 0 |
| Rep.3 | |
| Rep.4 | 0.1 |
| Rep.5 | 0.2 |
| Rep.6 | 0 |
| Rep.7 | |
| Rep.8 | 0.168 |
| Rep.9 | 0.084 |
| Rep.10 | 0.059 |
| Rep.11 | 0 |
| Rep.12 | 0 |

| Table | 2 : |
|---------------|------------|
| Preparation | Sample 1 |
| ID | Т |
| Potency | Assigned |
| Potency value | 80 IU/dose |
| Dose | 2.5 IU |
| Rep.1 | 0.042 |
| Rep.2 | 0.8 |
| Rep.3 | 0.1 |
| Rep.4 | 0.283 |
| Rep.5 | 0.141 |
| Rep.6 | 0.238 |
| Rep.7 | 0.283 |
| Rep.8 | 0.168 |
| Rep.9 | 0 |
| Rep.10 | 0 |
| Rep.11 | 0.168 |
| Rep.12 | 0.084 |

Has many advantages over parametric methods (e.g. t-test)

- No assumptions on normality nor homoscedasticity have to be made
- Applicable to various types of responses:

Quantal data (yes/no, e.g. lethal challenge)

Scores (e.g. intradermal challenge)

Quantitative data (e.g. ELISA absorbances)

Mixed data (e.g. quantitative data with a category "below detection limit")

- Not sensitive to outliers
- No transformation of responses is necessary
- In many practical cases, it is statistically more efficient than the t-test

However, for a single-dose assay to be valid, the condition of similarity of dose-response curves must be fulfilled



Limit tested

Limit test

| | | Limit tested | | | |
|-----------------|-----------|--------------|-------------|-----------------------|--|
| Preparation | Units | Value | Probability | Level of significance | |
| Sample 1: Batch | unit/dose | 0.5 | 0.007576 | ** | |

p-value ≤ 0.05 (usual significance threshold) → the 2 distributions of results differ significantly

| Table 1 | | | | |
|-----------------------------|-------------|--|--|--|
| Preparation Standard | | | | |
| ID | Reference | | | |
| Potency Assigned | | | | |
| Potency value | 1 unit/dose | | | |
| Diluted | 1 dose/2 ml | | | |
| Injected 0.5 ml/mou | | | | |
| Dose 1/1 | | | | |

| Tab | le 2 |
|---------------|--------------|
| Preparation | Sample 1 |
| ID | Batch |
| Potency | Assumed |
| Potency value | 1 unit/dose |
| Diluted | 1 dose/ml |
| Injected | 0.5 ml/mouse |
| Dose | 1/1 |

$$Limit \ value = \frac{1 \ unit}{1 \ dose} \times \frac{1 \ dose}{2 \ mL} \times \frac{0.5 \ mL}{1 \ mouse} \times \frac{1}{1} \times \left[\begin{array}{c} \text{From} \\ \text{Table 1} \end{array} \right]$$

$$\frac{1 \ dose}{1 \ unit} \times \frac{1 \ mL}{1 \ dose} \times \frac{1 \ mouse}{0.5 \ mL} \times \frac{1}{1} \left[\begin{array}{c} \text{From} \\ \text{Table 2} \end{array} \right]$$

 $Limit\ value = 0.5$

More precisely, Sample 1 has a potency significantly higher than 0.5 unit/dose

See the note for guidance, page 5 for further examples





Content

- ★ Data entry
- ★ Statistical analysis
- ★ Examples
- ★ Dose selection



Example 1

Multiple-dose assay

The signal increases with the dose (positive slope)

| Table 1 | | | | | |
|---------------|----------------|-----|-----|--|--|
| Preparation | Standard | | | | |
| ID | S | | | | |
| Potency | Assigned | | | | |
| Potency value | 5000 IU/mg | | | | |
| Dose | 1/45 1/30 1/20 | | | | |
| Rep.1 | 161 | 171 | 187 | | |
| Rep.2 | 150 | 172 | 192 | | |
| Rep.3 | 161 | 174 | 195 | | |
| Rep.4 | 163 | 184 | 194 | | |
| Rep.5 | 151 | 176 | 201 | | |
| Rep.6 | 166 182 198 | | | | |

| Table 2 | | | | |
|---------------|---------------------|-----|-----|--|
| Preparation | reparation Sample 1 | | | |
| ID | Т | | | |
| Potency | Assumed | | | |
| Potency value | 5600 IU/mg | | | |
| Dose | 1/45 1/30 1/20 | | | |
| Rep.1 | 170 | 188 | 204 | |
| Rep.2 | 161 | 180 | 202 | |
| Rep.3 | 161 | 172 | 203 | |
| Rep.4 | 170 | 181 | 209 | |
| Rep.5 | 164 | 191 | 212 | |
| Rep.6 | 171 196 203 | | | |

| 1 | 1/45 11.1111 IU | 1/30 166.6667 IU | | 1/20 250 IU | _ | |
|------------------------------------|--------------------|---------------------|-------------------------|----------------|----------|-----------------------|
| 210 - | 11.111110 | 200,000710 | | 250 10 | x x | |
| 200 - | | × | | / | X | |
| mation: y'=y) | | × | | • | | |
| Joseph 1907 | | | | | | |
| (No tra | | | | | | |
| Response (No transformation: y'=y) | × | × | | | | Potency |
| 160 - | × | | Preparation | Units | | Potency (LCL, UCL) |
| | × | ŗ | Preparation Sample 1: T | Units IU/mg | | - |

Single-dose assay

positive slope



| Table 1 | | | |
|---------------|-----------------------------------|----------------|-----|
| Preparation | paration Standard | | |
| ID | S | | |
| Potency | Assigned | | |
| Potency value | 5000 IU/mg | | |
| Dose | 1/45 1/30 1/20 | | |
| Rep.1 | 161 | 171 | 187 |
| Rep.2 | 150 172 192 | | |
| Rep.3 | 161 174 195 | | |
| Rep.4 | 163 | 184 | 194 |
| Rep.5 | 151 | 176 | 201 |
| Rep.6 | 166 | 182 | 198 |

| Table 2 | | | | |
|---------------|----------------------|----------------|------|--|
| Preparation | Preparation Sample 1 | | | |
| ID | Т | | | |
| Potency | Assumed | | | |
| Potency value | 5600 IU/mg | | | |
| Dose | 1/45 | 1/30 | 1/20 | |
| Rep.1 | 170 | 188 | 204 | |
| Rep.2 | 161 | 180 | 202 | |
| Rep.3 | 161 | 172 | 203 | |
| Rep.4 | 170 | 181 | 209 | |
| Rep.5 | 164 | 191 | 212 | |
| Rep.6 | 171 | 196 | 203 | |

The potency of Sample 1 is significantly **higher** (p=0.001) than 5000 IU/mg

Limit test

| | | Limit tested | | | |
|-------------|-------|--------------|-------------|-----------------------|--|
| Preparation | Units | Value | Probability | Level of significance | |
| Sample 1: T | IU/mg | 5000 | 0.001082 | ** | |






Example 2

Multiple-dose assay

The signal decreases with the dose (negative slope)

| Table 1 | | | | |
|---------------|----------------------|------|------|--|
| Preparation | Preparation Standard | | | |
| ID | S | | | |
| Potency | Potency Assigned | | | |
| Potency value | 5000 IU/mg | | | |
| Dose | 1/20 | 1/30 | 1/45 | |
| Rep.1 | 161 | 171 | 187 | |
| Rep.2 | 150 | 172 | 192 | |
| Rep.3 | 161 | 174 | 195 | |
| Rep.4 | 163 | 184 | 194 | |
| Rep.5 | 151 | 176 | 201 | |
| Rep.6 | 166 182 198 | | | |

| Table 2 | | | | |
|---------------|--------------------|------|------|--|
| Preparation | eparation Sample 1 | | | |
| ID | Т | | | |
| Potency | Assumed | | | |
| Potency value | 5600 IU/mg | | | |
| Dose | 1/20 | 1/30 | 1/45 | |
| Rep.1 | 170 | 188 | 204 | |
| Rep.2 | 161 | 180 | 202 | |
| Rep.3 | 161 | 172 | 203 | |
| Rep.4 | 170 | 181 | 209 | |
| Rep.5 | 164 | 191 | 212 | |
| Rep.6 | 171 | 196 | 203 | |



Single-dose assay

negative slope



| Table 1 | | | | |
|---------------|----------------------------|----------------|-----|--|
| Preparation | Standa | rd | | |
| ID | S | | | |
| Potency | Assigne | ed | | |
| Potency value | cency value 5000 IU/mg | | | |
| Dose | Dose 1/20 1/30 1/45 | | | |
| Rep.1 | 161 | 171 | 187 | |
| Rep.2 | 150 | 172 | 192 | |
| Rep.3 | 161 | 174 | 195 | |
| Rep.4 | 163 | 184 | 194 | |
| Rep.5 | 151 | 176 | 201 | |
| Rep.6 | 166 | 182 | 198 | |

| Table 2 | | | | |
|---------------|---------------------------|----------------|-----|--|
| Preparation | Sample | 1 | | |
| ID | Т | | | |
| Potency | otency Assumed | | | |
| Potency value | ency value 5600 IU/mg | | | |
| Dose | Dose 1/20 1/30 1/4 | | | |
| Rep.1 | 170 | 188 | 204 | |
| Rep.2 | 161 | 180 | 202 | |
| Rep.3 | 161 | 172 | 203 | |
| Rep.4 | 170 | 181 | 209 | |
| Rep.5 | 164 | 191 | 212 | |
| Rep.6 | 171 | 196 | 203 | |

The potency of Sample 1 is significantly lower (p=0.001) than 5000 IU/mg

Limit test

| | | Limit tested | | |
|-------------|-------|--------------|-------------|-----------------------|
| Preparation | Units | Value | Probability | Level of significance |
| Sample 1: T | IU/mg | 5000 | 0.001082 | ** |





Limit test interpretation

It is only possible to determine if the potency of the test preparation is lower or higher than the limit value if the signal-dose relationship is known

| | Signal-dose | relationship | | |
|--|--|--|--|--|
| Response of the test preparation | Results decrease when dose increases (negative slope) | Results increase with the dose (positive slope) | | |
| Lower than that of the standard | The potency of the test preparation is significantly higher than the limit value | The potency of the test preparation is significantly lower than the limit value | | |
| Greater than that of the standard | The potency of the test preparation is significantly lower than the limit value | The potency of the test preparation is significantly higher than the limit value | | |

E.g. Immunodiffusion test:

Limit value = $16700 \text{ IU/vial (p-value } \le 0.001)$

Results of the test preparation are higher than those of the standard.

→ The test preparation contains significantly [more]/[less] (please choose) than 16700 IU/vial





Example 3

The Wilcoxon-Mann-Whitney test also applies to quantal data

(the test corresponds to the Fisher's Exact test)


| Table 1 | | |
|---------------|-----------|--|
| Preparation | Standard | |
| ID | Reference | |
| Potency | Assigned | |
| Potency value | 8 IU/ml | |
| Dose | 1/300 | |
| Rep.1 | 20/28 | |

| Table 2 | | |
|---------------|-----------|--|
| Preparation | Sample 1 | |
| ID Potent I | | |
| Potency | Assumed | |
| Potency value | 2.5 IU/ml | |
| Dose | 1/30 | |
| Rep.1 | 10/28 | |

| Table 3 | | |
|--------------------|----------------|--|
| Preparation | Sample 2 | |
| ID | Sub-potent lot | |
| Potency | Assumed | |
| Potency value | 2.5 IU/ml | |
| Dose | 1/30 | |
| Rep.1 15/28 | | |

Limit test

| | | | Limit tested | | |
|--------------------------|-------|-------|--------------|-----------------------|--|
| Preparation | Units | Value | Probability | Level of significance | |
| Sample 1: Potent lot | IU/ml | 0.8 | 0.007562 | ** | |
| Sample 2: Sub-potent lot | IU/ml | 0.8 | 0.134734 | non-significant | |



For which interpretation?





Example 4

The calculation time of the **exact p-value** increases significantly with the number of data

| Table 1 | | | |
|-------------------------|----------------------|-----|--|
| Preparation | Preparation Standard | | |
| ID | S | | |
| Potency | Assigne | ed | |
| Potency value | 1 IU/dose | | |
| Dose | 1 dose 1 dose | | |
| Rep.1 | 10.1 | 4.4 | |
| Rep.2 | 8.5 12.2 | | |
| Rep.3 | 5.0 8.5 | | |
| Rep.4 | 6.0 8.5 | | |
| Rep.5 | 7.1 | 1.8 | |
| Rep.6 | 14.3 | 7.2 | |
| Rep.7 | 1.3 | 7.2 | |
| Rep.8 | 8.5 | 8.5 | |
| Rep.9 | 8.5 3.1 | | |
| Rep.10 14.3 10.2 | | | |

| Table 2 | | | | |
|---------------|----------|--------|--|--|
| Preparation | Sample 1 | | | |
| ID | Т | | | |
| Potency | Assume | ed | | |
| Potency value | ? IU/do: | se | | |
| Dose | 1 dose | 1 dose | | |
| Rep.1 | 0.1 | 10.2 | | |
| Rep.2 | 17.0 | 16.9 | | |
| Rep.3 | 12.0 | 11.7 | | |
| Rep.4 | 10.1 | 10.2 | | |
| Rep.5 | 3.0 | 10.2 | | |
| Rep.6 | 24.0 | 10.2 | | |
| Rep.7 | 20.2 | 8.4 | | |
| Rep.8 | 14.3 | 0.1 | | |
| Rep.9 | 8.5 | 0.1 | | |
| Rep.10 | 12.0 | 8.4 | | |



An approximated p-value based on the normal approximation with correction for ties is reported

Limit test

| | | Limit tested | | |
|-------------|---------|--------------|-------------|-----------------------|
| Preparation | Units | Value | Probability | Level of significance |
| Sample 1: T | IU/dose | 1 | 0.043519 | * |

Exact p-value = 0.043





Example 5 (1)

From multiple-dose assay...

single-dose assay... Lethal challenge (n=48 mice/lot)

| Table 1 | | |
|---------------|-------------|--|
| Preparation | Standard | |
| ID | S | |
| Potency | Assigned | |
| Potency value | 160 IU/vial | |
| Dose | Rep.1 | |
| 15.625 IU | 11/11 | |
| 6.25 IU | 12/12 | |
| 2.5 IU | 8/12 | |
| 1 IU | 4/10 | |

| 2 |
|------------|
| Sample 1 |
| Т |
| Assigned |
| 80 IU/dose |
| Rep.1 |
| 12/12 |
| 11/12 |
| 9/11 |
| 5/12 |
| |

Potency estimates

| | | Potency | | | |
|-------------|---------|----------|------------|----------|--|
| Preparation | Units | Estimate | (LCL, UCL) | | |
| Sample 1: T | IU/dose | 85.6132 | (41.3355, | 175.150) | |

Ph. Eur. monograph A lower confidence limit ≥ 32 IU/dose is required

to

Potency estimate & UCL not strictly needed and come at a high cost (48 mice/lot)

Is a single dose assay a better option?

| Table | 1 : | |
|---------------|------------------|--|
| Preparation | Standard | |
| ID | S | |
| Potency | Assigned | |
| Potency value | 160 IU/vial | |
| Dose | Rep.1 | |
| 15.625 IU | 11/11 | |
| 6.25 IU | 12/12 | |
| 2.5 IU | 8/12 | |
| 1 IU | 4/10 | |
| | | |

| Table | 2 |
|---------------|-----------------|
| Preparation | Sample 1 |
| ID | Т |
| Potency | Assigned |
| Potency value | 80 IU/dose |
| Dose | Rep.1 |
| 15.625 IU | 12/12 |
| 6.25 IU | 11/12 |
| 2.5 IU | 9/11 |
| 1 IU | 5/12 |

Limit test

| | | Limit tested | | | | | | |
|-------------|---------|--------------|-------------|-----------------------|--|--|--|--|
| Preparation | Units | Value | Probability | Level of significance | | | | |
| Sample 1: T | IU/dose | 32 | 0.063467 | non-significant | | | | |

If the lethal challenge assay was restricted to one dose, more than 12 mice/lot would be needed, but not as much as 48...



Example 5 (2)

Expected rates: Standard 1 IU: 40%; Vaccine lot 2.5 IU: 75%

Let's run the single-dose assay with n = 24 mice/lot

| | Std | Lot |
|------|--------------|--------------|
| n=24 | $\pi = 40\%$ | $\pi = 75\%$ |
| r | P(R = r) | P(R ≤ r) |
| 5 | 3% | 0% |
| 6 | 6% | 0% |
| 7 | 10% | 0% |
| 8 | 14% | 0% |
| 9 | 16% | 0% |
| 10 | 16% | 0% |
| 11 | 14% | 0% |
| 12 | 10% | 1% |
| 13 | 6% | 1% |
| 14 | 3% | 3% |
| 15 | 1% | 7% |
| 16 | 1% | 11% |
| 17 | 0% | 16% |
| 18 | 0% | 19% |
| 19 | 0% | 18% |
| 20 | 0% | 13% |
| 21 | 0% | 8% |
| 22 | 0% | 3% |

The most probable observed rates (Binomial dist.) are: Standard: 10/24 (42%) and Vaccine lot: 18/24 (75%)

| | | Limit tested | | | | | | | |
|-------------|---------------|--------------|-------------------|---|-------------------------|--|-------------|-----------------------|--|
| Preparation | aration Units | | Preparation Units | | Units Value Probability | | Probability | Level of significance | |
| Sample 1: T | IU/dose | 32 | 0.019605 | * | | | | | |

40 rates with a higher probabilities of occurrence

| 1 | 10/24 | 18/24 | 9 | 11/24 | 19/24 | 17 | 9/24 | 16/24 | 25 | 8/24 | 16/24 | 33 | 7/24 | 16/24 |
|---|-------|-------|----|-------|-------|----|-------|-------|----|-------|-------|----|-------|-------|
| 2 | 9/24 | 18/24 | 10 | 8/24 | 19/24 | 18 | 11/24 | 20/24 | 26 | 7/24 | 17/24 | 34 | 10/24 | 15/24 |
| 3 | 10/24 | 19/24 | 11 | 11/24 | 17/24 | 19 | 8/24 | 20/24 | 27 | 12/24 | 20/24 | 35 | 9/24 | 15/24 |
| 4 | 9/24 | 19/24 | 12 | 8/24 | 17/24 | 20 | 7/24 | 18/24 | 28 | 7/24 | 20/24 | 36 | 13/24 | 19/24 |
| 5 | 10/24 | 17/24 | 13 | 10/24 | 20/24 | 21 | 12/24 | 19/24 | 29 | 10/24 | 21/24 | 37 | 6/24 | 18/24 |
| 6 | 9/24 | 17/24 | 14 | 9/24 | 20/24 | 22 | 7/24 | 19/24 | 30 | 9/24 | 21/24 | 38 | 11/24 | 21/24 |
| 7 | 11/24 | 18/24 | 15 | 12/24 | 18/24 | 23 | 12/24 | 17/24 | 31 | 13/24 | 18/24 | 39 | 8/24 | 21/24 |
| 8 | 8/24 | 18/24 | 16 | 10/24 | 16/24 | 24 | 11/24 | 16/24 | 32 | 12/24 | 16/24 | 40 | 6/24 | 19/24 |

Proba. of occurrence (10/24; 18/24 as ref.)

| - | 0.80 | 0.61 | 0.51 | 0.36 |
|------|------|------|------|------|
| 1.00 | 0.80 | 0.60 | 0.51 | 0.36 |
| 0.95 | 0.73 | 0.60 | 0.44 | 0.36 |
| 0.95 | 0.72 | 0.60 | 0.42 | 0.36 |
| 0.86 | 0.71 | 0.58 | 0.41 | 0.35 |
| 0.86 | 0.71 | 0.56 | 0.41 | 0.34 |
| 0.85 | 0.61 | 0.53 | 0.38 | 0.34 |
| 0.84 | 0.61 | 0.52 | 0.37 | 0.33 |

p-values are \leq 0.05 in 30/40 (75%) cases, \leq 0.10 in 35/40 (88%) cases

p-values

| 0.020 | 0.018 | 0.041 | 0.021 | 0.010 |
|-------|-------|-------|-------|-------|
| 0.009 | 0.002 | 0.007 | 0.004 | 0.124 |
| 0.009 | 0.071 | 0.001 | 0.015 | 0.074 |
| 0.004 | 0.010 | 0.002 | 0.000 | 0.062 |
| 0.040 | 0.003 | 0.034 | 0.001 | 0.001 |
| 0.021 | 0.001 | 0.001 | 0.000 | 0.002 |
| 0.038 | 0.068 | 0.119 | 0.114 | 0.000 |
| 0.004 | 0.073 | 0.122 | 0.190 | 0.000 |

European Directorale | Direction européenne for the Quality | de la qualité of Medicines | du médicament & HealthCare | & soins de santé



Content

- ★ Data entry
- ★ Statistical analysis
- ★ Examples
- ★ Dose selection



Dose selection, limit test

1. Official requirements determine the best ratio between doses


"A lower confidence limit ≥ 32 IU/dose is required"

Preparations


| | | Information | Potency | | |
|----------|-------------|-------------|-------------------|-------------|--|
| Table | Preparation | ID | Potency | Value | |
| 1 | Standard ▼ | S | Assigned | 160 IU/vial | |
| 2 | Sample 1 ▼ | Т | Assigned ▼ | 80 IU/dose | |

Assigned potency = 80 IU/dose Ratio = 80/32 = 2.5 2. Experience determines the best absolute doses





Std: 0.8 IU, Spl: 2.0 IU



Std: 2.0 IU, Spl: 5.0 IU





Dose selection, limit test

1. Official requirements determine the best ratio between doses


"A lower confidence limit ≥ 32 IU/dose is required"

Preparations


| | | Information | Potency | | |
|----------|-------------|-------------|-------------------|-------------|--|
| Table | Preparation | ID | Potency | Value | |
| 1 | Standard ▼ | S | Assigned | 160 IU/vial | |
| 2 | Sample 1 ▼ | Т | Assigned ▼ | 80 IU/dose | |

Assigned potency = 80 IU/dose Ratio = 80/32 = 2.5 2. Experience determines the best absolute doses





Std: 0.8 IU, Spl: 2.0 IU



Std: 2.0 IU, Spl: 5.0 IU









CombiStats online Training module 4

Part 1: single-dose assays

Part 2: combination of assay results





Combination of assay results

Purpose: from n valid assay results to one result

Are estimates derived from independent assays?

Execution of either <u>does not affect</u> the probabilities of the possible outcomes of the other e.g. different runs, different days, different working solutions, ...

Assays on successive days using the original and retained dilutions of the standard are not independent assays.

Combination approach differs for **independent** and **not independent** assays

Ph. Eur. Chapter 5.3 Statistical analysis of results of biological assays and tests

- 1. introduction
- 2. randomisation and independence of individual treatments
- 3. assays depending upon quantitative responses
 - 3.2. the parallel-line model
 - 3.3. the slope-ratio model
 - 3.4. extended sigmoid dose-response curves
- 4. assays depending upon quantal responses
 - 4.2. the probit method
 - 4.3. the logit method
 - 4.5. the median effective dose
- 5. examples
- 6. combination of assay results
 - 6.2. combination of independent assay results
 - 6.3. unweighted combination of assay results
- 7. beyond this annex
- 8. tables and generating procedures
- 9. glossary of symbols
- 10. literature






Three types of combination of assay results

Potency results


| Entry | Preparation | ld. | Potency | Estimate | (LCL, UCL) | С | DF |
|-------|-------------|-----|--------------|----------|--------------------|--------------|----|
| 1 | Sample 1 | | 1000 IU / mg | 936.639 | (874.648, 1003.23) | 1.0107250215 | 25 |
| 2 | Sample 1 | | 1000 IU / mg | 970.838 | (919.331, 1026.05) | 1.0068245229 | 25 |
| 3 | Sample 1 | | 1000 IU / mg | 923.102 | (888.590, 958.767) | 1.0032881963 | 25 |



Homogeneity of assay results, p-value: 0.298


| Geometric | Potency (1000 IU/mg) | | | |
|---------------|----------------------|--------------------|--|--|
| combination | Estimate | (LCL, UCL) | | |
| Weighted | 938.014 | (912.564, 964.174) | | |
| Semi-weighted | 938.014 | (912.465, 964.279) | | |
| Unweighted | 943.314 | (884.424, 1006.12) | | |

95% confidence limits are reported.



Homogeneity test

The assay can be considered homogeneous if the variance between the individual estimates is not greater than those predicated by the individual confidence intervals



Evaluation based on p-value of χ^2 distribution:

- p-value >0.10 => potency estimates sufficiently homogeneous
- p-value ≤0.10 => potency estimates heterogeneous

Homogeneity of assay results, p-value: 0.298

| Geometric | Potency (1000 IU/mg) | | | | |
|---------------|----------------------|--------------------|--|--|--|
| combination | Estimate | (LCL, UCL) | | | |
| Weighted | 938.014 | (912.564, 964.174) | | | |
| Semi-weighted | 938.014 | (912.465, 964.279) | | | |
| Unweighted | 943.314 | (884.424, 1006.12) | | | |

95% confidence limits are reported.





Unweighted combination

Unweighted combination

 $Mean \pm t * SE$

t Student's statistic for n-1 degree of freedom (n number of assays)

SE standard error of mean

$$SE = \frac{1}{n}SD$$

Critical values of the t-distribution

| - | df 1 | 0 = 0.05 | 0.01 | df | p = 0.05 | p = 0.01 |
|---|------|----------|--------|-----|----------|----------|
|] | 1 | 12.706 | 63.656 | 22 | 2.074 | 2.819 |
| | 2 | 4.303 | 9.925 | 24 | 2.064 | 2.797 |
| 3 | 3 | 3.182 | 5.841 | 26 | 2.056 | 2.779 |
| 4 | 4 | 2.776 | 4.604 | 28 | 2.048 | 2.763 |
| 5 | 5 | 2.571 | 4.032 | 30 | 2.042 | 2.750 |
| 6 | 6 | 2.447 | 3.707 | 35 | 2.030 | 2.724 |
| 7 | 7 | 2.365 | 3.499 | 40 | 2.021 | 2.704 |
| 8 | 8 | 2.306 | 3.355 | 45 | 2.014 | 2.690 |
| 9 | 9 | 2.262 | 3.250 | 50 | 2.009 | 2.678 |
|] | 10 | 2.228 | 3.169 | 60 | 2.000 | 2.660 |
|] | 12 | 2.179 | 3.055 | 70 | 1.994 | 2.648 |
|] | 14 | 2.145 | 2.977 | 80 | 1.990 | 2.639 |
| 1 | 16 | 2.120 | 2.921 | 90 | 1.987 | 2.632 |
| 1 | 18 | 2.101 | 2.878 | 100 | 1.984 | 2.626 |
| 2 | 20 | 2.086 | 2.845 | 00 | 1.960 | 2.576 |
| | | | • | | | |

| Estimate | (LCL, UCL) | Confidence level | DF |
|----------|--------------------|------------------|----|
| 936.639 | (874.648, 1003.23) | 95 % | 25 |
| 970.838 | (919.331, 1026.05) | 95 % | 25 |
| 923.102 | (888.590, 958.767) | 95 % | 25 |

n is usually low



Large confidence interval

| Arithmetic | Poteno | cy (1000 IU/mg) | Rel. To Estimate (%) | | |
|---------------|----------|--------------------|----------------------|-----------------|--|
| combination | Estimate | (LCL, UCL) | Estimate | (LCL, UCL) | |
| Weighted | 937.362 | (911.560, 963.164) | 100 | (97.25, 102.75) | |
| Semi-weighted | 937.362 | (911.458, 963.266) | 100 | (97.24, 102.76) | |
| Unweighted | 943.526 | (882.411, 1004.64) | 100 | (93.52, 106.48) | |





Weighted combination

Weighted combination

Weighted Mean
$$\pm t * \sqrt{\frac{1}{\sum W}}$$


W weight calculated based on individual confidence interval

$$W = \frac{4t^2}{(UCL - LCL)^2}$$

t Student's statistic with DF equal to the sum of DF of residual error

Estimation of weights

$$W = \frac{1}{variance} = \frac{1}{SD^2}$$




$$UCL - LCL = \mu + t * SD - (\mu - t * SD)$$

= $\mu + t * SD - \mu + t * SD$
= $2 * t * SD$

$$\frac{(ULC - LCL)}{2 * t} = SD$$

| Estimate | (LCL, UCL) | Confidence level | DF |
|----------|--------------------|------------------|----|
| 936.639 | (874.648, 1003.23) | 95 % | 25 |
| 970.838 | (919.331, 1026.05) | 95 % | 25 |
| 923.102 | (888.590, 958.767) | 95 % | 25 |



More weight is given to the more precise results



W weight calculated based on individual confidence interval







Semi-weighted combination

Semi-weighted combination

Weighted' Mean
$$\pm 2 * \sqrt{\frac{1}{\sum W'}}$$

W weight calculated based on intra- and inter-assay variation

$$W' = \frac{1}{intra^2 + inter^2}$$

intra-assay variation

$$intra^2 = \frac{1}{W}$$


same W as calculated for weighted combination

inter-assay variation

$$inter^{2} = \frac{\sum (M - \overline{M})^{2}}{n - 1} - \frac{\sum intra^{2}}{n}$$

n number of assays M assay estimate \overline{M} mean of estimates

| Estimate | (LCL, UCL) | Confidence level | DF |
|----------|--------------------|------------------|-----|
| 774.169 | (750.584, 798.498) | 95 % | inf |
| 737.265 | (714.811, 760.428) | 95 % | inf |
| 817.927 | (793.001, 843.639) | 95 % | inf |



Intra- and inter-assay variation



Enlarged confidence interval

Homogeneity of assay results, p-value: < 0.001

| Arithmetic | Uni | ts (ug/ED50) | Rel. To Estimate (%) | | |
|---------------|----------|--------------------|----------------------|-----------------|--|
| combination | Estimate | (LCL, UCL) | Estimate | (LCL, UCL) | |
| Weighted | 773.656 | (759.822, 787.491) | 100 | (98.21, 101.79) | |
| Semi-weighted | 776.194 | (729.570, 822.818) | 100 | (93.99, 106.01) | |
| Unweighted | 776.454 | (676.146, 876.761) | 100 | (87.08, 112.92) | |

95% confidence limits are reported.

Unweighted RSD(%): 5.2





Three types of combination of assay results



Weighted $Mean \pm t * \sqrt{\frac{1}{\sum W}}$

t sum of DF of residual errorsW weight calculated based on individual result only

Semi-weighted combination



W' weight calculated based on intra-and inter assay variation

Unweighted combination

 $Mean \pm t * SE$

n number of results

t Student's statistic for n-1
degree of freedom
SE standard error of mean

Combined potency estimates are different (depending on weights)

Smaller confidence interval

Enlarged confidence interval


Usually larger confidence interval





Combine assays in CombiStats online

Select the assays in a folder



Condition for combination:


- analysis results should be present
- assay must be published

For sigmoid curve models potency estimates or effective doses can be combined


Or combine opened assays



Combine assay results



- Potency estimates O Effective dose
- Assays that can be combined:
- A302 Erythromycin Assay 1 PLA Blocks
- A303 Erythromycin Assay 2 PLA Blocks
- A304 Erythromycin Assay 3 PLA Blocks







Available Options

Combination of assay results



I can write ...

Information about assays

| Entry | Assay name | Project | Assay |
|-------|--------------------------------------|--------------|-------|
| 1 | A302 Erythromycin Assay 1 PLA Blocks | Erythromycin | 1 |
| 2 | A303 Erythromycin Assay 2 PLA Blocks | Erythromycin | 2 |
| 3 | A304 Erythromycin Assay 3 PLA Blocks | Erythromycin | 3 |

Potency results

| Entry | Preparation | ld. | Potency | Estimate | (LCL, UCL) | Confidence level | DF |
|-------|---------------------|-----|--------------|----------|--------------------|------------------|---------------|
| 1 | Sample 1 | Т | 1000 IU / mg | 936.639 | (874.648, 1003.23) | 95 % | 25 |
| 2 | Sample 1 | Т | 1000 IU / mg | 970.838 | (919.331, 1026.05) | 95 % | 25 |
| 3 | Sample 1 | U | 1000 IU / mg | 923.102 | (888.590, 958.767) | 95 % | 25 |

Combine by



Confidence level

95 %

Integer between 80 and 99

Only fields Remark, Combine by and Confidence level for combination can be **modified**

The content of Information about assays and Potency results **cannot be modified**

One or more potency results can be excluded by **double- click**

Once the options chosen, run the analysis







Arithmetic and geometric combination

Geometric combination

Potency results

| Entry | Preparation | ld. | Potency | Estimate | (LCL, UCL) | Confidence level | DF |
|-------|-------------|-----|--------------|----------|--------------------|------------------|----|
| 1 | Sample 1 | | 1000 IU / mg | 936.639 | (874.648, 1003.23) | 95 % | 25 |
| 2 | Sample 1 | | 1000 IU / mg | 970.838 | (919.331, 1026.05) | 95 % | 25 |
| 3 | Sample 1 | | 1000 IU / mg | 923.102 | (888.590, 958.767) | 95 % | 25 |

CombiStats software

- ✓ applies log-transformation to estimates and confidence limits,
- ✓ performes calculations on the log-scale,
- ✓ appies anti-log-function on final results

Arithmetic combination

If the estimates are already on the log scale, no transformation prior to the combination

Effective dose results

| Entry | Preparation | ld. | Units | Estimate | (LCL, UCL) | Confidence level | DF |
|-------|-------------|-----|-----------------|----------|--------------------|------------------|-----|
| 1 | Sample 1 | Α | log10 ED50/vial | 4.73374 | (4.45322, 5.01399) | 95 % | inf |
| 1 | Sample 2 | Α | log10 ED50/vial | 3.59821 | (3.31617, 3.87813) | 95 % | inf |

CombiStats software

✓ performes calculations on the log-scale

If potency unit contains "**log**", <u>arithmetic combination only</u> is displayed. Otherwise, geometric combination presented by defaults. User has the possibility to change to arithmetic combination





Combined results

Combined by Preparation

Potency results

| Entry | Preparation | Id. | Potency | Estimate | (LCL, UCL) | Confidence level | DF |
|-------|-------------|-----|--------------|----------|--------------------|------------------|----|
| 1 | Sample 1 | Т | 1000 IU / mg | 936.639 | (874.648, 1003.23) | 95 % | 25 |
| 2 | Sample 1 | Т | 1000 IU / mg | 970.838 | (919.331, 1026.05) | 95 % | 25 |
| 3 | Sample 1 | U | 1000 IU / mg | 923.102 | (888.590, 958.767) | 95 % | 25 |

Combine by

Confidence level

Preparation Sample 1

Geometric combination

Homogeneity of assay results, p-value: 0.298

| Geometric | Poten | cy (1000 IU/mg) | Rel. To Estimate (%) | | Rel. To Assumed/Assigned (%) | |
|---------------|----------|--------------------|----------------------|-----------------|------------------------------|-----------------|
| combination | Estimate | (LCL, UCL) | Estimate | (LCL, UCL) | Estimate | (LCL, UCL) |
| Weighted | 938.014 | (912.564, 964.174) | 100 | (97.29, 102.79) | 93.80 | (91.26, 96.42) |
| Semi-weighted | 938.014 | (912.465, 964.279) | 100 | (97.28, 102.80) | 93.80 | (91.25, 96.43) |
| Unweighted | 943.314 | (884.424, 1006.12) | 100 | (93.76, 106.66) | 94.33 | (88.44, 100.61) |

95% confidence limits are reported.

Unweighted gCV(%): 2.6

Potency **units** should be the same (case sensitive) If potency **values** not the same, no Rel. to Assumed/Assigned (%)


Potency results

| Entry | Preparation | ld. | Potency | Estimate | (LCL, UCL) | Confidence level | DF |
|-------|-------------|-----|--------------|----------|--------------------|------------------|----|
| 1 | Sample 1 | Т | 1000 IU / mg | 936.639 | (874.648, 1003.23) | 95 % | 25 |
| 2 | Sample 1 | Т | 1000 IU / mg | 970.838 | (919.331, 1026.05) | 95 % | 25 |
| 3 | Sample 1 | Т | ? IU / mg | 923.102 | (888.590, 958.767) | 95 % | 25 |

Combine by

Confidence level





Preparation Sample 1

Geometric combination

Homogeneity of assay results, p-value: 0.298

| Geometric | Pote | ency (IU/mg) | Rel. To Estimate (%) | | |
|---------------|----------|--------------------|----------------------|-----------------|--|
| combination | Estimate | (LCL, UCL) | Estimate | (LCL, UCL) | |
| Weighted | 938.014 | (912.564, 964.174) | 100 | (97.29, 102.79) | |
| Semi-weighted | 938.014 | (912.465, 964.279) | 100 | (97.28, 102.80) | |
| Unweighted | 943.314 | (884.424, 1006.12) | 100 | (93.76, 106.66) | |

95% confidence limits are reported.

Unweighted gCV(%): 2.6





Useful links

★ Helpdesk

https://helpdesk.edqm.eu/servicedesk/customer/user/login?destination=portals

★ Institutional website

https://www.edqm.eu/en/lp-combistats

★ FAQs, privacy, security notices

https://combistats.edqm.eu/help/

★ User guide (sign in first)

https://combistats.edqm.eu/user-manuals/combistats_user_guide.pdf/











@edqm_news







European Directorate | Direction européenn for the Quality | de la qualité of Medicines | du médicament & HealthCare | & soins de santé



© EDQM 2025